Brian Keegan, MD, PhD

In this discussion, panelists offer their final thoughts.

In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.

A panel of experts discuss the key updates needed in CSU guidelines, as they have not been updated since 2014.

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.

A panel of experts discuss using systemic corticosteroids in CSU treatment.

A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.

Stanley Goldstein, MD, discusses which therapies are typically used initially for CSU patients.

A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU.

Stanley Goldstein, MD, discusses the differential diagnosis when considering CSU.

Giselle Mosnaim, MD, discusses the epidemiology that is associated with CSU.

Experts on chronic spontaneous urticaria outline the hallmark symptoms most associated with the disease and how they fluctuate with time.

A panel of experts describe the pathophysiology of chronic spontaneous urticaria.